Patterns of anxiety and distress over 12 months following participation in HPV primary screening.


Journal

Sexually transmitted infections
ISSN: 1472-3263
Titre abrégé: Sex Transm Infect
Pays: England
ID NLM: 9805554

Informations de publication

Date de publication:
06 2022
Historique:
received: 09 09 2020
accepted: 29 05 2021
pubmed: 5 8 2021
medline: 20 5 2022
entrez: 4 8 2021
Statut: ppublish

Résumé

Many countries are now using primary human papillomavirus (HPV) testing for cervical screening, testing for high-risk HPV and using cytology as triage. An HPV-positive result can have an adverse psychological impact, at least in the short term. In this paper, we explore the psychological impact of primary HPV screening over 12 months. Women were surveyed soon after receiving their results (n=1133) and 6 (n=762) and 12 months (n=537) later. Primary outcomes were anxiety (Short-Form State Anxiety Inventory-6) and distress (General Health Questionnaire-12). Secondary outcomes included concern, worry about cervical cancer and reassurance. Mixed-effects regression models were used to explore differences at each time point and change over time across four groups according to their baseline result: control (HPV negative/HPV cleared/normal cytology and not tested for HPV); HPV positive with normal cytology; HPV positive with abnormal cytology; and HPV persistent (ie, second consecutive HPV-positive result). Women who were HPV positive with abnormal cytology had the highest anxiety scores at baseline (mean=42.2, SD: 15.0), but this had declined by 12 months (mean=37.0, SD: 11.7) and was closer to being within the 'normal' range (scores between 34 and 36 are considered 'normal'). This group also had the highest distress at baseline (mean=3.3, SD: 3.8, scores of 3+ indicate case-level distress), but the lowest distress at 12 months (mean=1.9, SD: 3.1). At 6 and 12 months, there were no between-group differences in anxiety or distress for any HPV-positive result group when compared with the control group. The control group were less concerned and more reassured about their result at 6 and 12 months than the HPV-positive with normal cytology group. Our findings suggest the initial adverse impact of an HPV-positive screening result on anxiety and distress diminishes over time. Specific concerns about the result may be longer lasting and efforts should be made to address them.

Identifiants

pubmed: 34344834
pii: sextrans-2020-054780
doi: 10.1136/sextrans-2020-054780
pmc: PMC9120391
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-261

Subventions

Organisme : Cancer Research UK
ID : C7492/A17219
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C49896/A17429
Pays : United Kingdom
Organisme : Department of Health
ID : DRF‐2017‐10‐105
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Health Psychol Rev. 2021 Sep;15(3):395-429
pubmed: 32449477
Int J Cancer. 2018 Aug 15;143(4):735-745
pubmed: 29341110
Cochrane Database Syst Rev. 2017 Aug 10;8:CD008587
pubmed: 28796882
Int J Gynecol Cancer. 2019 Apr 24;:
pubmed: 31018938
Int J Cancer. 2019 Jul 1;145(1):29-39
pubmed: 30549273
BMJ. 2019 Feb 6;364:l240
pubmed: 30728133
Br J Cancer. 2005 Mar 28;92(6):990-4
pubmed: 15785734
Psychooncology. 2019 Oct;28(10):1959-1970
pubmed: 31411787
BJOG. 2004 Dec;111(12):1437-43
pubmed: 15663132
PLoS One. 2011;6(6):e21046
pubmed: 21698168
Int J Cancer. 2020 Apr 15;146(8):2113-2121
pubmed: 31251820
Br J Clin Psychol. 1992 Sep;31(3):301-6
pubmed: 1393159
Int J Gynecol Cancer. 2008 Jul-Aug;18(4):743-8
pubmed: 17944916
BMJ. 2004 May 29;328(7451):1293
pubmed: 15166066
BMJ Open. 2016 Dec 23;6(12):e014356
pubmed: 28011816

Auteurs

Laura A V Marlow (LAV)

Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK l.marlow@kcl.ac.uk.
Research Department of Behavioural Science and Health, University College London, London, UK.

Emily McBride (E)

Research Department of Behavioural Science and Health, University College London, London, UK.

Deborah Ridout (D)

UCL Great Ormond Street Institute of Child Health, University College London, London, UK.

Alice S Forster (AS)

Research Department of Behavioural Science and Health, University College London, London, UK.

Henry Kitchener (H)

Women's Cancer Centre, Institute of Cancer Sciences, The University of Manchester, Manchester, UK.

Jo Waller (J)

Cancer Prevention Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Research Department of Behavioural Science and Health, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH